Pelthos Therapeutics Inc.
PTHS
Get informed when a big investor buys or sells
+ FollowMarket Cap$71.25M
Close$
$31.94
58.5% upside
Current Fair Value
58.5% upsideUndervalued by 58.5% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $71.25 Million |
|---|---|
| Enterprise Value | $93.66 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-23.04 |
| Beta | 3.11 |
| Outstanding Shares | 3,539,464 |
Return
| Return on Equity | 4767.29% |
|---|---|
| Return on Assets | -52.10% |
| Return on Invested Capital | -28.62% |
Valuation & Multiples
| P/E Ratio | -0.49 |
|---|---|
| PEG | -0.08 |
| Price to Sales | 1.68 |
| Price to Book Ratio | -20.15 |
| Enterprise Value to Revenue | 2.16 |
| Enterprise Value to EBIT | -3.1 |
| Enterprise Value to Net Income | -2 |
| Total Debt to Enterprise | 0.5 |
| Debt to Equity | -31.05 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 13, 2026
EPS Estimate
$-2.82
Average shareholder expectationRevenue Estimate
$15.17 M
Average shareholder expectationNext Earnings Call
Expected Date
November 12, 2026
EPS Estimate
$-2.97
Average shareholder expectationRevenue Estimate
$17.59 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 37.38%▲ 9.84% |
|---|---|
| Total Invested | $37.39M▲ 95.08% |
| Investors Holding | 23▲ 6.00% |
ESG Score
No data
About Pelthos Therapeutics Inc.
92 employees
CEO: Scott Plesha Pelthos Therapeutics Inc. operates as a biopharmaceutical enterprise dedicated to developing and commercializing innovative medical treatments that address significant, unmet patient needs. Its primary offerings include ZELSUVMI, a medic...